CONRAD CORDOVA: Open Payments
NPI 1215382460 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,986 in 29 payments from 17 companies in 2025. Trend: 2023 $2,607 · 2024 $3,777 · 2025 $2,986
Food & beverage: $2,986
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $375 |
| Alexion Pharmaceuticals, Inc. | 3 | $336 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $251 |
| Janssen Biotech, Inc. | 2 | $250 |
| Eisai Inc. | 2 | $244 |
| Teva Pharmaceuticals USA, Inc. | 2 | $224 |
| TG Therapeutics, Inc. | 2 | $170 |
| Abbott Laboratories | 4 | $136 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| ARGENX US, INC. | 1 | $125 |
Products named: ULTOMIRIS, CAPLYTA, TREMFYA, TEZSPIRE, Leqembi, AUSTEDO XR, BRIUMVI, DUPIXENT.
Industry payments across AZ — which companies pay providers there.
